Catalyzing the Next Generation of Precision Medicines
AI-driven enzyme and targeted drug design to build better therapeutics.
Platform
Experiment-informed AI
The Ridge Bio platform uses proprietary machine learning models built on massive cell-free datasets to design precision enzymes and targeted delivery systems at unprecedented speed and scale.
Our unique wet-lab and generative AI capabilities enable us to take on biotechnology’s most challenging problems from constructing superior antibody-drug conjugates (ADCs) to engineering novel biocatalysts, driving the development of safer, more effective medicines for patients.
Product Lines
Bringing New Functions to Precision Medicines
NativeLink
Precision Conjugation for Better Therapeutics
NativeLinkTM enzymes modify diverse classes of proteins and peptides efficiently and site-specifically without changing their producing cell line or using non-standard amino acids. See how our NativeLink-AXC product enables homogeneous functionalization of antibodies or existing ADC drug products with multiple payloads to generate ADCs, AOCs, radiopharmaceuticals, and other antibody conjugates with stable linkages to expand therapeutic indices – all without altering disulfide bonds, glycans, or protein sequences.
ProTrigger
Precision Linkers for Targeted Therapy
ProTriggerTM linkers conditionally activate or release payloads in target tissues. Using deep protease expertise and datasets to inform custom-built ML models, we design linkers to reduce off-tumor toxicity and unlock new extracellular or poorly-internalizing targets for ADCs by triggering in the tumor microenvironment or stroma. Our linkers can provide an additional AND logic gate for diverse modalities, driving the development of safer therapies.
Catalytic Medicines
Precision Enzymes for Challenging Targets
We are developing new classes of highly specific enzyme-based therapeutics with differentiated mechanisms of action to hit hard to reach, highly abundant, or difficult drug targets. By applying our precision enzyme engineering platform with select partners, we seek to create therapies for unmet clinical needs.
Partnership Areas
Ridge Bio Unlocks
Extended Half-life for Peptides and Biologics
Enhance stability and reduce dosing frequency by functionalization of peptides or biologics using designer enzymes.
New Chemical Space for Small Molecules
Enable novel reactions and scaffolds inaccessible through traditional chemistry for efficient production of existing or novel APIs.
Disease or Tissue-specific Targeting
Achieve wider therapeutic windows and hit new targets with bespoke enzyme-activated linkers and probodies that trigger in specific tissues.
Novel Bioconjugates and Multi-specifics
Rapidly tune the valency, specificity, and payloads of highly uniform, site-specific conjugates including ADCs, AOCs, radiotherapies, and peptide-drug conjugates.
Enzyme Therapeutics
Improve enzyme replacement therapies or enable new catalytic mechanisms of action for difficult drug targets with AI-enabled biologically-informed enzyme design.
Precision Nucleic Acid Delivery
Pioneer genetic medicine with efficient targeting and delivery of in vivo CAR-Ts, siRNA, ASOs, mRNA, and lipid nanoparticles.
Team
Leadership and Advisory Board
“Drug development should never be limited by the complexity of molecules we can precisely construct, off-target toxicities, or binding-based mechanisms of action. At Ridge, we overcome these challenges using ML and massive cell-free datasets, empowering our partners to build better medicines for patients.”
“Ridge Bio is the perfect example of our approach to building companies: back world-class founders and help them attract the incredible teams they need to solve tough technical problems and unlock huge markets. Ridge Bio’s capabilities across machine learning and wet lab bioengineering positions the company to build drugs that no one else can.”
“Ridge Bio is at the forefront of three key trends, next-generation bioconjugates, protein design, and enzymatic therapeutics. They enable drug developers to really differentiate themselves from competitors, not only through improved manufacturing but also through improved therapeutic indices.”
